Our top pick for
Nephros Inc is a medical instruments & supplies business based in the US. Nephros shares (NEPH) are listed on the NASDAQ and all prices are listed in US Dollars. Nephros employs 27 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$7.51|
|52-week range||$5.69 - $10.20|
|50-day moving average||$8.46|
|200-day moving average||$8.46|
|Wall St. target price||$13.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.38|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-3.10%|
|1 month (2021-09-21)||-12.78%|
|3 months (2021-07-21)||-18.72%|
|6 months (2021-04-21)||0.54%|
|1 year (2020-10-21)||12.93%|
|2 years (2019-10-21)||-22.97%|
|3 years (2018-10-19)||1,177.43%|
|5 years (2016-10-20)||2,175.76%|
|Revenue TTM||$9.5 million|
|Gross profit TTM||$4.9 million|
|Return on assets TTM||-14.34%|
|Return on equity TTM||-25.19%|
|Market capitalisation||$79.3 million|
TTM: trailing 12 months
There are currently 16,265 Nephros shares held short by investors – that's known as Nephros's "short interest". This figure is 11.2% down from 18,319 last month.
There are a few different ways that this level of interest in shorting Nephros shares can be evaluated.
Nephros's "short interest ratio" (SIR) is the quantity of Nephros shares currently shorted divided by the average quantity of Nephros shares traded daily (recently around 7071.7391304348). Nephros's SIR currently stands at 2.3. In other words for every 100,000 Nephros shares traded daily on the market, roughly 2300 shares are currently held short.
However Nephros's short interest can also be evaluated against the total number of Nephros shares, or, against the total number of tradable Nephros shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nephros's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Nephros shares in existence, roughly 0 shares are currently held short) or 0.0034% of the tradable shares (for every 100,000 tradable Nephros shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Nephros.
Find out more about how you can short Nephros stock.
We're not expecting Nephros to pay a dividend over the next 12 months.
Nephros's shares were split on a 1:9 basis on 9 July 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nephros shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Nephros shares which in turn could have impacted Nephros's share price.
Over the last 12 months, Nephros's shares have ranged in value from as little as $5.69 up to $10.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nephros's is 1.3566. This would suggest that Nephros's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Nephros, Inc. , a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.